Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.
Zacks·21h ago
More News
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks·2d ago
FDA APPROVES TEZSPIRE FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
FDA APPROVES TEZSPIRE FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS FDA APPROVES TEZSPIRE FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS PR Newswire THOUSAND OAKS, Calif., Oct. 17, 2025 Approval...
PR Newswire·5d ago
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.
Zacks·5d ago
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
Zacks·6d ago
Amgen (AMGN) Laps the Stock Market: Here's Why
In the closing of the recent trading day, Amgen (AMGN) stood at $297.32, denoting a +1.18% move from the preceding trading day.
Zacks·7d ago
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.
Zacks·8d ago
Why Amgen (AMGN) Could Beat Earnings Estimates Again
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·9d ago
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
Zacks·12d ago
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.